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Background: Eukaryotic ubiquitin and SUMO are frequently used as tags to enhance the fusion protein expression
in microbial host. They increase the solubility and stability, and protect the peptides from proteolytic degradation
due to their stable and highly conserved structures. Few of prokaryotic ubiquitin-like proteins was used as fusion
tags except ThiS, which enhances the fusion expression, however, reduces the solubility and stability of the
expressed peptides in E. coli. Hence, we investigated if MoaD, a conserved small sulfur carrier in prokaryotes with
the similar structure of ubiquitin, could also be used as fusion tag in heterologous expression in E. coli.
Results: Fusion of MoaD to either end of EGFP enhanced the expression yield of EGFP with a similar efficacy of
ThiS. However, the major parts of the fusion proteins were expressed in the aggregated form, which was associated
with the retarded folding of EGFP, similar to ThiS fusions. Fusion of MoaD to insulin chain A or B did not boost their
expression as efficiently as ThiS tag did, probably due to a less efficient aggregation of products. Interestingly,
fusion of MoaD to the murine ribonuclease inhibitor enhanced protein expression by completely protecting the
protein from intracellular degradation in contrast to ThiS fusion, which enhanced degradation of this unstable
protein when expressed in E. coli.
Conclusions: Prokaryotic ubiquitin-like protein MoaD can act as a fusion tag to promote the fusion expression with
varying mechanisms, which enriches the arsenal of fusion tags in the category of insoluble expression.
Keywords: MoaD, Prokaryote, Ubiquitin, Expression, Degradation, Protein foldingBackground
Fusion expression is a common strategy in the production
of recombinant proteins. Various fusion tags are used to
enhance the total and soluble expression yield in E. coli.
Fusion tags show differing efficiency in enhancing the ex-
pression, solubility and stability of recombinant proteins
[1-5]. The stable or conserved structure of the fusion tag
is speculated as a determinant of its fusion properties [6].
Ubiquitin (Ub) and SUMO are stable, highly conserved
small proteins expressed in all eukaryotic cells. They are
frequently used as tags to enhance the fusion expression
by increasing the solubility and stability of the expressed
peptides and protecting the peptides from proteolytic* Correspondence: wangnan@imm.ac.cn
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stated.degradation in prokaryotic host [6-8]. MoaD and ThiS,
components of prokaryotic sulfur transfer systems, are
also highly conserved small proteins found in prokary-
otic cells. They display a high degree of structural simi-
larity although sharing limited sequence similarities to
Ub, and interact with correlating enzymes in similar
ways as Ub [9-12]. They are Ub-like proteins (Ubl) and
have been suggested as prokaryotic antecedents of Ub.
Prokaryotic ThiS was also tried as a fusion tag in expres-
sion of heterologous proteins in E. coli [13]. It was able
to induce aggregation of fusion proteins due to a slow-
down of refolding, and enhance the expression of some
targets more significantly than its eukaryotic counterpart
Ub. But it promoted the degradation of unstable target
fusion.
In this report, we observed the effect of fusion of
MoaD, a small prokaryotic ubl containing 81 amino acid
residues, on the expression of several targets in E. coli.d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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ThiS in enhancing the recombinant expression and pro-
moting the aggregation of fusion proteins through slow-
down of target folding. Contrary to ThiS fusion, MoaD
fusion conferred a complete protection of the murine ribo-
nuclease inhibitor (mRI) from intracellular degradation.
Results
MoaD fusion enhances the expression of EGFP
The gene encoding EGFP was fused in frame to the gene
of MoaD either at upstream or at downstream, and was
cloned into prokaryotic expression vector pQE30. Simi-
lar constructs via ThiS fusion were used as the controls.
All these MoaD-fused EGFP were expressed more
abundantly than EGFP alone in E. coli TG1 at 37°C
(Figure 1A).
The fluorescence of cells expressing EGFP with or
without fusions was measured after IPTG induction.
The intensity of fluorescence increased steadily at 37°C.
The fluorescence was normalized to the measured OD600,
since a slight but significant difference in OD600 was no-
ticed among the cells, although they grew at the similar
rate (Figure 1B). The normalized intensity of fluores-
cence thus was in direct proportion to the emitted
fluorescence of single cell in average. The fluorescence
of the cells bearing EGFP alone reached to a plateau
after 1 h induction at 37°C (Figure 1B). N-terminal
MoaD fusion gave a continued increase in normalized
fluorescence which was much higher than EGFP alone
after 2 h induction at 37°C. N-terminal ThiS fusion
emitted much lower fluorescence. The cells bearing
C-terminal fusion of MoaD had significantly lower
fluorescence than cells bearing EGFP alone. C-terminal
fusion of ThiS also caused significantly lower fluo-
rescence than EGFP alone, consisting to the previous
report [13].
Since the accumulation of non-native EGFPs in in-
clusion bodies could have reduced the measured
fluorescence, we did similar experiments with lower
concentration of inducer and under lower cultured
temperature in expecting to improve the soluble expres-
sion and reduce the inclusion body formation. Indeed,
higher fluorescence was reached for all the recombi-
nants (Figure 1C). Nevertheless, much less fluorescence
had been observed in both N-terminal MoaD fusion and
N-terminal ThiS fusion than EGFP alone. Interestingly,
even less fluorescence was observed in the C-terminal
MoaD fusion under the same conditions. Whereas the
C-terminal ThiS fusion produced an identical fluo-
rescence as did EGFP alone at room temperature. The
discrepancy in growing fluorescence may reflect the
difference in relative amount of soluble active proteins
and insoluble fluorescent folding intermediates, as pre-
viously identified [13].MoaD fusion promotes the aggregation of EGFP
To verify whether the difference in fluorescence growing
patterns could be attributed to the differential soluble
expression of the fusions, cells were analyzed for their
expression in native form in soluble portion and non-
native one in aggregation by SDS-PAGE. We found that
EGFPs with or without fusions were expressed in inclu-
sion bodies at 37°C (Figure 2A and B). Similarly, we ana-
lysed the whole cell lysates from milder induction at lower
cultured temperature by SDS-PAGE without boiling de-
naturation, which separated the native EGFP proteins in
soluble form from their non-native molecules in inclusion
bodies [13]. The EGFP without tag was predominantly
expressed in native form at room temperature (Figure 2C
and D). Major parts of N-terminal and C-terminal fused
EGFP with MoaD were expressed in non-native form as
compared to EGFP without tag. C-terminal fusion of
MoaD had even much less native active fluorescent pro-
tein compared to that of EGFP alone and ThiS fusion,
which was consistent to the observation that much less
in vivo fluorescence of C-terminal MoaD fusion was in-
duced at room temperature (Figure 1C).
To further elucidate the difference in soluble expression
of C-terminal fusion of MoaD from that of ThiS fusion
and EGFP alone, we analysed the fluorescence distribution
within cells by confocal microscopy. As shown in Figure 3,
the inclusion bodies were present within all the cells even
under leaky expression conditions. The fluorescence was
evenly distributed in the cells expressing EGFP alone
or with ThiS fusion. The fluorescence in cells with
C-terminal MoaD fusion was chiefly segregated in the
inclusion bodies (Figure 3 lowest panel). This was con-
sistent with the observation illustrated in Figure 2D.
These results suggest that fusion of EGFP with MoaD
at either N- or C-terminus enhances the expression of
the fusion protein which presents mostly as aggregated
inclusion bodies in a similar way as fusions with ThiS.
MoaD fusion retards the refolding of EGFP
The enhanced aggregation of EGFP by C-terminal ThiS
fusion was previously attributed to the reduced refolding
rate of EGFP [13]. Hence, we evaluated the foldability of
N-terminal fusion of EGFP with MoaD or ThiS. Purified
fluorescent EGFP with fusions was denatured and rena-
tured in vitro. Upon dilution, both fused proteins refolded
gradually with an increase in fluorescence, the same as
EGFP alone (Figure 4). MoaD-fused EGFP had the same
final recovery of fluorescence as did EGFP alone, whereas
ThiS-fused EGFP had a slightly lower final recovery of
fluorescence. Both MoaD- and ThiS-fused EGFP refolded
at a significantly slower rate either in fast or slow refolding
phases (indicated by lower k1 and k2 values in Figure 4).
The soluble fluorescent C-terminal MoaD fused EGFP
was subjected to rapid in vitro fragmentation after
Figure 1 (See legend on next page.)
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Figure 1 Enhanced expression of EGFP fused with MoaD. (A) The recombinant EGFP proteins without fusion (EGFP), and with MoaD-tag
fused at N-terminus (left panels) or C-terminus (right panels), were induced by 1 mM IPTG for 4 h at 37°C. ThiS-tag fusions were used as positive
control. Total cell lysates were resolved on 12% SDS-PAGE (upper panels) and analyzed by immunoblot with anti His-tag antibody (lower panels).
(B) At 37°C induced by 1 mM IPTG or (C) at room temperature induced by 0.1 mM IPTG, cell growth (black lines) was recorded by measuring
absorbance at 600 nm, and the fluorescence of cells was measured (excitation 488 nm; emission 509 nm) and normalized to corresponding
OD600 (blue lines). Triangle is for EGFP, open circle for ThiS fusion, and solid circle for MoaD fusion. Each point represents mean and SD of 4
independent experiments. *p < 0.05; **p < 0.01 comparing to EGFP control.
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ability was not identified.
MoaD is inefficient in enhancing the expression of insulin
A and B chains
Since ThiS fusion enhanced the expression of insulin
chain A and B [13], we also fused the gene of MoaD to
the gene encoding insulin chain A or B at their upstream
and cloned into prokaryotic expression vector pET28a.
The fusion proteins were expressed in much less amount
in E. coli BL21 (DE3) pLysS by IPTG induction, in com-
parison to the ThiS fusions as control (Figure 5A and B,
left panels). Anti-His-tag immunoblot (Figure 5A and B,
right panels) of the proteins revealed that MoaD fusions
had relatively more proportion in soluble form in com-
parison to ThiS fusions.
MoaD fusion protects murine Ribonuclease Inhibitor from
degradation
As fusion of ThiS enhanced the degradation of the un-
stable protein mRI when expressed in E. coli [13], we tried
to observe the effect of fusion of MoaD on the stability of
mRI. It was shown in SDS-PAGE (Figure 6A and B) that
MoaD-fused mRI was expressed at expected molecular
weight in inclusion bodies, both in strain TG1 and in the
Lon protease deficient E. coli strain BL21 (DE3) pLysS. No
degraded fragments of MoaD fusion were noticed in
Western blots, indicating a complete protection of mRI
from degradation by MoaD fusion, in contrast to the
enhanced degradation by fusion of ThiS.
It seemed that breakdown occurred more frequently
at C-terminus of mRI [13,14]. A mutated mRI, with a
merely single mutation which changed Glu340 to a stop
coden at C-terminal part in mRI, was fused to MoaD or
ThiS. The prematurely stopped and thus slightly shor-
tened products of both fusions were efficiently overex-
pressed in full length in TG1 and BL21 (DE3) pLysS.
Only faintly stained smaller fragments were observed for
ThiS fusion (Figure 6C), which was different from that
of native mRI in Figure 6A and B. It suggested that tar-
get itself determined its degradability in vivo when fused
to ThiS. The MoaD fusion product remained intact
without any degradation. This proved again that MoaD
fusion protected the target from degradation.Discussion
A variety of fusion tags are used to increase expression
yields and change solubility and native folding [15].
However, it is still not clear how fusion tags enhance
protein expression. Ub was reported to exert chapero-
ning effects on fusion proteins, thus increase expression
of proteins in E. coli and yeast [7,16]. Indeed, Ub has a
highly stable structure and is the fastest folding protein
known [17]. Thus, it may serve to stabilize and promote
proper folding of the fusion target. SUMO, structurally
similar to Ub, also promotes folding and structural sta-
bility of fusion proteins, and leads to their enhanced ex-
pression [18-20].
Prokaryotic MoaD and ThiS share the structure of
Ub-like domain with their eukaryotic counterparts Ub
and SUMO. Our current results indicate that MoaD
confers the enhanced expression of EGFP, either in
N-terminal fusion or in C-terminal fusion. In contrast to
eukaryotic counterparts Ub and SUMO, MoaD fusion at
both N- and C-terminus reduces the soluble protein ex-
pression rather than enhances the solubility. This is the
same case for ThiS fusion. Instead of promoting its proper
folding in refolding experiments, MoaD hinders the native
EGFP folding, in a similar way to ThiS. This was not
expected because they are stable small proteins with a
similar conserved structure as Ub or SUMO. The slow-
down of folding, rather than the fast expression of fusion
protein, should be a primary factor to drive the expressed
fusion protein to inclusion bodies. This was proved by
the fact that the most of EGFP with MoaD fusion at
C-terminus are aggregated in inclusion bodies as detected
by confocal microscopy. Actually, the fast expression of
fusion protein should not occur under the leaky expres-
sion condition.
Enhancing the production of inclusion bodies is one of
the fusion strategies although fewer tags are reported for
this purpose [15]. Inclusion bodies protect the products
from proteolyses, and usually lead to a higher expression
yield. In this study, MoaD did not drive the satisfied over-
expression of insulin A and B chains in comparison to the
ThiS fusions because of a decreased ability of MoaD in
driving the protein aggregation of insulin chains.
Different fusion systems have given variable results of
expression [1,3,4], and no single fusion tag is ideal for
Figure 2 Enhanced aggregation of EGFP in fusion with MoaD. In the upper panel, the recombinant proteins of EGFP fused with MoaD at
N-terminus (A) or C-terminus (B), were induced by 1 mM IPTG for 4 h at 37°C. EGFP alone without fusion, and fusions with ThiS were used as
control. Total cell lysate (T) and the soluble (S) or insoluble (I) fractions were resolved on 12% SDS-PAGE. All the proteins were mainly expressed
in the inclusion bodies. In the lower panel, the cells were induced with 0.1 mM IPTG at room temperature for 20 h. Unboiled total cell lysates of
fusions at N-terminus (C) or C-terminus (D) were resolved on 12% SDS-PAGE. The soluble native form was separated from insoluble denatured
form for each sample (a). Their ratios were calculated and compared to that of EGFP (b), *p < 0.05 for triplicate experiments; # p < 0.05 for
comparison between ThiS- and MoaD-fusion. The Western blot with His-tag antibody (c) and UV illuminated gel (d) further confirmed the
identities of overexpressed products and corresponding native forms.
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Figure 3 Fluorescence distribution of EGFP fusion proteins within E. coli. E. coli TG1 bearing EGFP without fusion or with C-terminal ThiS or
MoaD fusion was cultured overnight at 37°C without IPTG induction. Cells on cover slide were subjected to confocal microscopy with laser
excitation at 488 nm. Representative photos were shown in left panels as fluorescence images, middle panels as phase contrast images with
inclusion bodies indicated by arrows, and right panels as their merged images. Scale bar in each photo represents 3.75 μm.
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MoaD fusion affords complete protection of the product
from intracellular degradation. Ub- and SUMO-fusion of
mRI, although leading expression products to inclusion
bodies, show a moderate intracellular degradation of
products [13]. This difference may be attributed to the
rapid aggregation of MoaD fusion product to inclusion
bodies that afford protection from proteolytic degradation.
On the other hand, ThiS fusion, expected to enhance the
rapid aggregation due to the sluggish of folding in a simi-
lar way as MoaD fusion, led to the significant degradation
of mRI. An active ThiS-directed degradation was antici-
pated for this unusual observation [13].Conclusions
This work shows that MoaD, as a fusion tag, is able to
promote expression of some target proteins as expected
from its structural similarity to Ub and SUMO. While
unexpectedly, MoaD enhances the aggregation of fusion
proteins due to a slowdown of refolding, the same as the
typical prokaryotic ubl ThiS. Furthermore, MoaD fusion
provides an advantage over ThiS in protecting the un-
stable target from degradation. Hence, in addition to
ThiS, MoaD enriches the arsenal of fusion tags in the
category of insoluble expression. Expression in inclusion
bodies may be required specifically in cases where pro-
tein production is toxic to the host cell. It is feasible for
Figure 4 In vitro refolding of EGFP in fusion with MoaD. The
refolding kinetics of N-terminal fusion of EGFP with MoaD (red line)
and ThiS (blue line) were compared in vitro to that of EGFP without
fusion (black line) in the upper panel, which represents an averaged
result of the short term refolding curves from three independent
experiments, with fluorescence (normalized to the respective final
fluorescence recovered) plotted against time. In the lower panel,
kinetics of an initial fast refolding phase, the following slow refolding
phase, and the percentage of refolding at final stage (15 h) were
compared to EGFP control. *p < 0.05; **p < 0.01
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sion of some target proteins.Methods
Materials
Biochemicals were purchased from Sigma (St. Louis,
MO). Ni-IDA agarose affinity resin was from Vigorous
Biotechnology (Beijing, China). Oligonucleotides were
from Invitrogen (Shanghai, China). All restriction enzymes
and T4 DNA ligase were from TaKaRa (Dalian, China).
Pfu DNA Polymerase and LA Taq DNA Polymerase were
from Vigorous Biotechnology (Beijing, China).E. coli strains
E. coli TG1 cells were used for cloning, maintenance and
propagation of plasmids. TG1 and BL21 (DE3) pLysS cells
were used as host for protein expression studies. E. coli
cells were cultivated in Luria broth under appropriate
selective conditions.Construction of expression vectors
Standard molecular biology techniques were applied for
cloning [21]. All recombinant DNA/constructs were
verified by sequencing (Invitrogen, Shanghai, China).
All primers used are shown in Table 1.
MoaD and ThiS genes were amplified from genomic
DNA of E. coli strain TG1. Insulin genes for chain A
and B were synthesized as described Yuan et al. [13].
Gene fusions were made by restricted fragment ligation.
A cDNA of mRNH coding mRI (with 456 amino acid
residues) [14] and its PCR amplified spontaneous mu-
tant (coding truncated product ΔmRI due to Glu340 was
mutated to a stop code) were used for gene fusions.
The expression vectors were based on the pQE30
plasmid (Qiagen, Hilden, Germany) with hexa-His at
5’ fusion, pVI plasmid (Vigilance Biotechnology, Beijing,
China) with sept-His at 5’ fusion, or pET28a plasmid
(Invitrogen, Carlsbad, CA, USA) with hexa-His at 5’ fu-
sion. All the expression plasmids and their expected
products were shown in Table 2.Expression and purification of recombinant proteins
The culture of E. coli was grown overnight and subcul-
tured at 1:100 into Luria broth at 37°C. When the cell
growth of the culture reached a mid-log phase, protein
expression was induced by adding Isopropyl β-D-1-thio-
galactopyranoside (IPTG) to a final concentration of
1 mM, with a further 4 h growth at 37°C, or otherwise
indicated. Cells were harvested, resuspended in PBS
containing 1% Triton X-100, subjected to cycles of
freezing and thawing, and then disrupted using soni-
cation. The soluble protein fraction was separated from
insoluble one by centrifugation at 4°C (15 min at
14,000 g). Soluble fraction of His-tagged recombinant
proteins were purified by nickel-affinity chromato-
graphy under native conditions based on the supplier’s
instructions.Electrophoresis and Western blot
The samples of whole cells or the purified protein frac-
tions were mixed with Laemmli buffer, either heated in
boiling water bath for 5 min or not heated, and ana-
lyzed by SDS-PAGE, as described by Laemmli [22],
using a 5% stacking gel and a 10% to 15% separating
gel run in a Mini-Protean II electrophoresis system
(BioRad, Hercules, CA, USA). The gels were stained
with Coomassie Blue, or electroblotted onto nitrocel-
lulose or PVDF membranes. His-tagged fusions were
detected by immunoblot using anti-His antibody and
goat anti-mouse HRP labelled antibody (CoWin
Biotech, Beijing, China). Chemiluminescence was re-
corded using the reagents according to supplier’s
protocol (CoWin Biotech, Beijing, China).
Figure 5 Expression of insulin chains with MoaD fusion. Insulin A chain (upper panel) or B chain (lower panel) fused with MoaD at their N-termini,
were expressed in E. coli BL21 (DE3) pLysS. ThiS-fused chains were used as control. Total cell lysate from uninduced (−) or induced (+) cells with IPTG,
and the soluble (S) or insoluble fraction (I) of induced cells were electrophoresed on 15% SDS-PAGE, shown in left panel. Expressed proteins were verified
by Western blot probed with anti His-tag antibody, shown in right panel. Arrows highlight expressed proteins at expected positions.
Figure 6 Expression of mRI and its C-terminal truncated mutant in fusion with MoaD. mRI with MoaD fusion were expressed in (A) E. coli
TG1 or (B) E. coli BL21 (DE3) pLysS. ThiS-fused mRI was used as control. Total cell lysates from uninduced (−) or induced (+) cells with IPTG, and
the soluble (S) or insoluble fraction (I) of induced cells were resolved on 10% SDS-PAGE, shown in each upper panel. Western blot probed by anti
His-tag antibody was shown in each lower panel. (C) C-terminal truncated mRI (△mRI) in fusion with MoaD or ThiS were also expressed in E. coli
TG1 and BL21 (DE3) pLysS. Expressed products migrating at the expected molecular weight are indicated by arrows.
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Table 1 Primers used in this study
Primer Primer sequence/featured site* PCR product: coding protein
1: ThiS up ATAagatctATGCAGATCCTGTTTAACGATC /Bgl II primers 1 + 2: ThiS.
2: ThiS down ATAgaattcAACCCCCTGCAATAACC /EcoR I
3: ThiS down ATAggatccCCCTGCAATAACCTGAAAAAG /BamH I primers 1 + 3: ThiS for fusion to N-terminus of targets
4: MoaD up ATAagatctATTAAAGTTCTTTTTTTCGCCCAG / Bgl II primers 4 + 5: MoaD for fusion to N-terminus of targets
5: MoaD down ATAggatccTCCGGTTACCGGCGGG / BamH I
6: MoaD down ATActcgagTTAACCTCCGGTTACCGGCGGG /Xho I primers 4 + 6: MoaD for fusion to C-terminus of targets
7: A up ATAagatctATGGGCATTGTGGAACAGTGCTGCAC /Bgl II primers 7 + 8: insulin chain A
8: A down ATActcgagTTAGTTGCAATAGTTTTCCAGCTG /Xho I primers 4 + 8: MoaD fusion to A
9: B up ATAagatctATGTTTGTGAACCAGCATCTGTG /Bgl II primers 9 + 10: insulin chain B
10: B down ATActcgagTTAGGTTTTCGGGGTATAAAAAAAG /Xho I primers 4 + 10: MoaD fusion to B
11: EGFP up ATAggatccATGGTGAGCAAGGGCGAGGAGCTG /BamH I primers 11 + 12: EGFP
primers 11 + 6: MoaD fusion to C-terminus of EGFP
12: pEGFP-C-3’ TATGGCTGATTATGATCAGT /universal vector primer primers 11 + 12: EGFP for fusion at C-turminus
13: EGFP down ATActcgagTCACTTGTACAGCTCGTCCATG /Xho I primers 11 + 13: EGFP for fusion at N-turminus
primers 1 + 13: ThiS fusion to N-terminal EGFP
primers 4 + 13: MoaD fusion to N-terminal EGFP
14: RNH up ATAagatctATGAGTCTTGACATCCAGTGTGAGC /Bgl II primers 14 + 15: mRI
15: RNH down ATAgtcgacTCAGGAAATGATCCTCAGGGAAGG /Sal I primers 1 + 15: ThiS fusion to ΔmRI
primers 7 + 15: MoaD fusion to mRI or ΔmRI
*Restriction site in lowercase.
Table 2 Strains and plasmids used in this study
Strain or plasmid Description Source or reference
E. coli strain Host background
TG1 K-12 strain Stratagene
BL21(DE3)pLysS B strain with Lon protease deficiency, contains pLysS plasmid expressing T7 lysozyme Novagen
Plasmid Expressed protein MW*
EGFP/pQE30 EGFP with his-tag at N-terminus, with extra 22 vector sequences. 30578 Previous study [13]
ThiS-EGFP/pQE30 ThiS fused to N-terminus of EGFP with his-tag at N-terminus. 35719 This study
EGFP-ThiS/pQE30 ThiS fused to C-terminus of EGFP with his-tag at N-terminus. 36133 Previous study [13]
MoaD-EGFP/pQE30 MoaD fused to N-terminus of EGFP with his-tag at N-terminus. 37093 This study
EGFP-MoaD/pQE30 MoaD fused to C-terminus of EGFP with his-tag at N-terminus. 37506 This study
ThiS-A/pET28a ThiS fused Insulin A chain with his-tag at N-terminus. 13438 Previous study [13]
ThiS-B/pET28a ThiS fused Insulin B with his-tag at N-terminus. 14484 Previous study [13]
MoaD-A/pET28a MoaD fused Insulin A chain with his-tag at N-terminus. 14812 This study
MoaD-B/pET28a MoaD fused Insulin B with his-tag at N-terminus. 15858 This study
ThiS-mRNH/pVI ThiS fused mRI with his-tag at N-terminus. 58661 Previous study [13]
MoaD-mRNH/pVI MoaD fused mRI with his-tag at N-terminus. 60034 This study
ThiS-ΔRNH/pVI ThiS fused ΔmRI with his-tag at N-terminus. 45672 This study
MoaD-ΔRNH/pVI MoaD fused ΔmRI with his-tag at N-terminus. 47045 This study
*Molecular weight of each protein product was calculated based on the predicted protein sequence from corresponding plasmid.
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The fluorescence of purified soluble EGFPs was mea-
sured with excitation wavelength at 488 nm and emis-
sion wavelength at 509 nm using EnSpire Multimode
Reader (Perkin-Elmer, Waltham, MA, USA). For E. coli
expressing recombinant EGFP proteins, cultured media
containing live whole cells was aliquoted and the fluo-
rescence was measured promptly, the same way as puri-
fied proteins. The bacteria concentration of the same
sample was also measured as absorbance at 600 nm.
Confocal microscopy
E. coli in LB-medium that expressing recombinant EGFP
proteins were dropped onto a slide and sealed with a
coverslip. Images were recorded with a confocal laser
scanning microscope (Leica TCS SP2, Leica Laser-technik,
Heidelberg, Germany) either in phase contrast mode or
fluorescence mode (wavelengths at 488 nm for excitation,
and 500–560 nm for detection).
Denaturation and refolding of EGFP
Purified ThiS- or MoaD-tagged EGFP and EGFP without
fusion were denatured in PBS containing 8 M urea and
5 mM DTT for 5 min in a boiling water bath. Urea-
denatured samples were renatured at room temperature
by 10-fold dilution into PBS with 5 mM DTT. Fluores-
cence recovery was monitored with an interval of 5 s for
50 min. Data were fitted with Sigma Plot (Systat Software,
San Jose, CA, USA) and kinetics for fast and slow refol-
ding phases obtained as described [23]. Final refolding
was measured at 15 h. The percentage of refolding was
calculated on the basis of the final constant amount of
fluorescence, corresponding to the amount of fluorescence
before denaturation.
Statistical analysis
The results were derived from three to four independent
experiments. The Student’s t-test for paired samples was
used to calculate the p values. The statistical analyses
were performed using SPSS 13.0 (IBM SPSS, Armonk,
NY, USA), and p values less than 0.05 were considered
statistically significant.
Additional file
Additional file 1: Figure S1. In vitro fragmentation of EGFP fused with
MoaD at C-terminus.
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